XMRV Discovery and Prostate Cancer-Related Research

Abstract EN

Xenotropic murine leukemia virus-related virus (XMRV) was first reported in 2006 in a study of human prostate cancer patients with genetic variants of the antiviral enzyme, RNase L.

Subsequent investigations in North America, Europe, Asia, and Africa have either observed or failed to detect XMRV in patients (prostate cancer, chronic fatigue syndrome-myalgic encephalomyelitis (CFS-ME), and immunosuppressed with respiratory tract infections) or normal, healthy, control individuals.

The principal confounding factors are the near ubiquitous presence of mouse-derived reagents, antibodies and cells, and often XMRV itself, in laboratories.

XMRV infects and replicates well in many human cell lines, but especially in certain prostate cancer cell lines.

XMRV also traffics to prostate in a nonhuman primate model of infection.

Here, we will review the discovery of XMRV and then focus on prostate cancer-related research involving this intriguing virus.